University of Chicago Medical Center, Chicago, Illinois; Department of Medicine, Chicago, Illinois.
University of Chicago Medical Center, Chicago, Illinois; Department of Surgery, Chicago, Illinois.
J Card Fail. 2017 Oct;23(10):762-764. doi: 10.1016/j.cardfail.2017.05.018. Epub 2017 Jun 13.
Until recently, transplantation from hepatitis C-positive donors was relatively contraindicated as eradication of active hepatitis C previously required an interferon-based regimen that has been associated with rejection in solid organ transplantation. New interferon-free treatment regimens for hepatitis C have fewer adverse events and higher cure rates than interferon-based regimens. Interferon-free regimens have been shown to be safe in the liver transplantation literature, but little is known about the safety and efficacy of treatment in heart transplantation.
Here we report a case of successful eradication of hepatitis C with a non-interferon-based regimen using ledipasvir-sofosbuvir following combined orthotopic heart and liver transplantation. Based on the prevalence of hepatitis C in the general population, inclusion of hepatitis C-positive donors for heart transplantation can expand this component of the donor pool 3- to 6-fold.
In carefully selected patients and recipients, inclusion of hepatitis C-positive donors may allow for expansion of the donor pool.
直到最近,从丙型肝炎阳性供体移植相对禁忌,因为以前根除丙型肝炎需要一种基于干扰素的方案,而这种方案与实体器官移植中的排斥反应有关。新的无干扰素治疗丙型肝炎方案比基于干扰素的方案具有更少的不良事件和更高的治愈率。无干扰素方案在肝移植文献中已被证明是安全的,但在心脏移植中治疗的安全性和疗效知之甚少。
我们在这里报告了一例联合原位心脏和肝脏移植后使用 ledipasvir-sofosbuvir 成功根除丙型肝炎的非干扰素方案的病例。根据丙型肝炎在普通人群中的流行率,将丙型肝炎阳性供体纳入心脏移植可以将供体库扩大 3 至 6 倍。
在经过仔细选择的患者和受者中,纳入丙型肝炎阳性供体可能会扩大供体库。